ABIOMED (ABMD) PT Raised to $250.00

ABIOMED (NASDAQ:ABMD) had its price objective increased by analysts at Jefferies Group to $250.00 in a research note issued to investors on Friday, The Fly reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. Jefferies Group’s price target suggests a potential upside of 16.22% from the company’s current price.

Several other analysts have also commented on ABMD. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $213.00 target price for the company in a research note on Friday, December 29th. Piper Jaffray Companies reissued a “buy” rating on shares of ABIOMED in a research note on Thursday, January 4th. SunTrust Banks reissued a “buy” rating and set a $195.00 target price on shares of ABIOMED in a research note on Wednesday, November 1st. Finally, BTIG Research reissued a “hold” rating on shares of ABIOMED in a research note on Sunday, October 29th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. ABIOMED has an average rating of “Buy” and a consensus price target of $199.67.

Shares of ABIOMED (NASDAQ:ABMD) opened at $215.11 on Friday. The firm has a market cap of $9,510.00, a P/E ratio of 105.97, a PEG ratio of 2.84 and a beta of 0.15. ABIOMED has a one year low of $103.53 and a one year high of $216.15. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company had revenue of $132.80 million during the quarter, compared to analyst estimates of $131.18 million. During the same period in the prior year, the business posted $0.20 EPS. The business’s revenue for the quarter was up 28.9% compared to the same quarter last year. research analysts anticipate that ABIOMED will post 2.41 earnings per share for the current year.

In other news, Director Dorothy E. Puhy sold 6,364 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the sale, the director now owns 39,532 shares in the company, valued at $7,079,390.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the sale, the vice president now owns 56,757 shares in the company, valued at approximately $10,139,070.48. The disclosure for this sale can be found here. 7.00% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. Seven Eight Capital LP acquired a new stake in shares of ABIOMED during the second quarter valued at approximately $100,000. Crow Point Partners LLC acquired a new stake in shares of ABIOMED during the fourth quarter valued at approximately $120,000. Rehmann Capital Advisory Group acquired a new stake in shares of ABIOMED during the third quarter valued at approximately $202,000. Sigma Planning Corp acquired a new stake in shares of ABIOMED during the third quarter valued at approximately $206,000. Finally, Dorsey & Whitney Trust CO LLC acquired a new stake in shares of ABIOMED during the third quarter valued at approximately $215,000. Institutional investors and hedge funds own 90.45% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “ABIOMED (ABMD) PT Raised to $250.00” was originally posted by American Banking and Market News and is owned by of American Banking and Market News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/14/abiomed-abmd-pt-raised-to-250-00.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.